Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
736 6 |
Ultima descărcare din IBN: 2021-11-10 10:49 |
SM ISO690:2012 TARAN, Natalia, DUMBRAVA, Vlada-Tatiana, TOFAN-SCUTARU, Liudmila. Hepatocarcinomul celular: răspândire, factori de risc şi obţiuni de tratament. In: Sănătate Publică, Economie şi Management în Medicină , 2014, nr. 5(56), pp. 138-142. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | ||||||
Numărul 5(56) / 2014 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
Pag. 138-142 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Liver cancer ranks the 6th place in the structure of oncological morbidity (749000 new cases) and third in cancer mortality structure (692000), representing 7% of all cancer cases. HCC represents more than 90% of primary liver cancer, being the primordial public health problem worldwide. Globally, approximately 54% of HCC cases causally relate to viral hepatitis B (400 million people), 31% of cases are caused by viral hepatitis C (170 million people infected) and the rest – 15% have other causes. The basic treatment of HCC is surgical. When properly selected, candidates resection and liver transplantation offers the best option for development (5-year survival rate is achieved in 60-80% of cases) and there are methods of choice in patients with early-stage tumors. |
||||||
Cuvinte-cheie viral chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, treatment methods, liver transplantation |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Taran, N.V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Dumbrava, V.A.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Tofan-Scutaru, L.G.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='ro'>Hepatocarcinomul celular: răspândire, factori de risc şi obţiuni de tratament</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2014</publicationYear> <relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1729-8687</relatedIdentifier> <subjects> <subject>viral chronic hepatitis</subject> <subject>liver cirrhosis</subject> <subject>liver transplantation</subject> <subject>hepatocellular carcinoma</subject> <subject>risk factors</subject> <subject>treatment methods</subject> </subjects> <dates> <date dateType='Issued'>2014-10-31</date> </dates> <resourceType resourceTypeGeneral='Text'>Journal article</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p><em>Liver cancer ranks the 6th place in the structure of oncological morbidity (749000 new cases) and third in cancer mortality structure (692000), representing 7% of all cancer cases. HCC represents more than 90% of primary liver cancer, being the primordial public health problem worldwide. Globally, approximately 54% of HCC cases causally relate to viral hepatitis B (400 million people), 31% of cases are caused by viral hepatitis C (170 million people infected) and the rest – 15% have other causes. The basic treatment of HCC is surgical. When properly selected, candidates resection and liver transplantation offers the best option for development (5-year survival rate is achieved in 60-80% of cases) and there are methods of choice in patients with early-stage tumors.</em></p></description> <description xml:lang='ru' descriptionType='Abstract'><p><em>Рак печени занимает 6-е место в структуре онкологической заболеваемости (749000 новых случаев) и 3-е место в структуре онкологической смертности (692000 случаев) и составляет 7% всех случаев рака. На ГЦК приходится более 90% первичных раковых опухолей печени, что представляет большую проблему здравоохранения во всем мире. В мире около 54% случаев ГЦК связаны с гепатитом В (им страдает 400 млн. человек), 31% случаев обусловлены гепатитом С (им заражено 170 млн. человек), а остальные 15% приходятся на другие причины. Основное лечение ГЦК — хирургическое. У хорошо подобранных кандидатов резекция и трансплантация печени обеспечивают наилучшие исходы (5-летняя выживаемость достигает 60–80%) и служат методом выбора у пациентов с </em><em>ранней стадией опухоли.</em></p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>